文献速递肝病消化道肿瘤与早癌

免疫检查点抑制剂联合治疗肝细胞癌的机制依据

Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.
PubMed 文献 · Hepatology · 2021-06-21

本文综述肝细胞癌免疫检查点抑制剂联合治疗的机制依据。纳武利尤单抗单药在晚期肝细胞癌的应答率为20%,但大部分患者无应答,促使探索联合策略。临床前与临床研究提示联合治疗可能产生协同抗肿瘤效应,但指导联合方案最大化的机制依据尚不明确。

要点

  • 纳武利尤单抗单药治疗晚期肝细胞癌的应答率为20%。
  • 免疫检查点抑制剂与其他疗法联合可能产生协同抗肿瘤效应。
  • 不同药物联合实现协同的机制依据尚不明确,需进一步阐明。

核心结论

  • 免疫检查点抑制剂联合其他治疗可能产生协同抗肿瘤效应,但指导联合方案最大化的机制依据尚不明确。

研究设计与样本

  • 本文为综述,讨论肝细胞癌中不同药物联合方案及其潜在机制依据。

主要发现

  • 纳武利尤单抗单药在晚期肝细胞癌的应答率为20%。
  • 大部分患者对免疫检查点抑制剂无应答,驱动探索提高疗效的治疗策略。
  • 近期临床前与临床研究提示免疫检查点抑制剂联合使用或与其他抗癌疗法联用可能产生协同抗肿瘤效应。

临床怎么用

  • 综述旨在加深对肝细胞癌联合治疗如何实现协同的理解,为开发更有效联合方案奠定基础。

局限性

  • 指导不同药物联合以最大化协同效应的机制依据在很大程度上仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is one of the deadliest cancers because of late symptom manifestation leading to delayed diagnosis, which limits patients with HCC in terms of receiving curative surgical treatment. There are only a few therapeutic options for patients with advanced HCC. The emergence of immune checkpoint inhibitors (ICIs) brings HCC treatment to a stage at which nivolumab, an anti-programmed cell death protein 1 monoclonal antibody, achieves a 20% response rate. However, the large proportion of unresponsive patients drives the exploration of therapeutic strategies to improve ICIs' efficacy. Recent preclinical and clinical studies have suggested that ICIs, when used in combinations or when used with other cancer therapies, might elicit synergistic antitumor effects. However, the mechanistic rationales guiding different drug combinations to maximize this synergy remain largely ambiguous. In this review, we discuss different drug combinations used in HCC and the underlying mechanistic rationales, aiming to enhance the understanding of how these treatments can achieve synergy. This knowledge sets the foundation for the development of more effective and promising combination therapies for HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Cheu JW, Wong CC. Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. Hepatology. 2021. PMID: 33811765. doi:10.1002/hep.31840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。